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ABSTRACT 
Chemerinwas recently added to the adipokine family and was identified in human ovarian follicles and 
follicular fluid that suggests a direct correlation between chemerin and PCOS. Asymmetric dimethyl 
arginine (ADMA) is involved in endothelial dysfunctionthe  atherogenic potential of ADMA has been 
investigated in young patients with PCOS. Oxidative stress is considered to be implicated in the 
pathophysiology of PCOS.Paraoxonase 1 (PON1) is an antioxidant enzyme and its concentration has 
been shown to be inversely associated with oxidative stress. Objectives: Evaluation of serum chemerin, 
ADMA, PON1in obese and non-obese polycystic ovarian patients to postulate their role in pathogenesis 
of PCOS. Methods: Ninetynuligravida women aged 20-35 (60 with PCOS and 30 controls) were 
recruited. Fasting blood was obtained on day 2 or 3 of the menstrual cycle. Clinical evaluation, 
hormonal profile, Chemerin, ADMA and PON1 were assessed.  Results: There was a significant 
increase in serum chemerinlevels  in PCOS obese group when compared with PCOS non obese patients 
and healthy controls non obese and obese respectively. Serum ADMA level was increased significantly 
in PCOS obese group as compared to the PCOS  non obese group , control non obese  and control obese. 
Paraoxonase was decreased stepwise significantly from the control non obese group and control obese 
group to PCOS non obese patients then PCOS obese patients to. Conclusions: it could be suggested that 
increased chemerin has a role in PCOS development andaltered ADMA and PON1 associated 
withobesity and oxidative stress may exacerbate the condition. 
 
Introduction
Polycystic ovary syndrome (PCOS) is the most frequent 
endocrine disorder among women of reproductive age, 
affecting 5–10% of all women in their life span and it is 
in focus of research because of its increasing 
prevalence[1]. No single diagnostic criteria are sufficient 
for its clinical diagnosis. The revised diagnostic criteria 
of PCOS include any two of the following three features, 
oligoor anovulation,clinical and/or biochemical 
hyperandrogenemiaand lastly the finding of polycystic 
ovaries on ultrasound scan, with exclusion of other 
etiologies [2]. 
The etiology of this complex heterogeneous disorder is 
still uncertain. Environmental factors such as physical 
inactivity, malnutrition, obesity and insulin resistance 
(IR) have crucial role in development of the disorder [3]. 
These factors might lead to the endothelial dysfunction 
which is observed before the onset of clinically 
manifested vascular diseases, mainly and cardiovascular 
risk in PCOS. The endogenous nitric oxide synthase 
inhibitor; asymmetric dimethyl arginine (ADMA) 
represents an independent marker for endothelial 
dysfunction and cardiovascular morbidity [4]. 
Dysfunction of adipose tissue has been implicated in the 
pathophysiology of PCOS. Increasing evidence shows 
that the dysregulated expression of adipokines, the 
secreted products of adipose tissue, plays an important 
role in the pathology of PCOS [5]. 
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These adipokines include adiponectin, leptin, omentin, 
resistin, retinol binding protein-4(RBP-4), tumor necrosis 
factor-α (TNF-α), interleukin-6 (IL6), vaspin, visfatin 
and chemerin[6]. 
Chemerin is a novel adipokine that regulates adipocyte 
development and metabolic function. In humans, plasma 
chemerin concentrations are correlated with body fat, 
glucose, lipidmetabolismand inflammation. Plasma 
chemerin concentrations are elevated in patients with 
obesity and / or DM [7]. Chemerin has been shown to be 
expressed in mouse ovary and placenta and in human 
placenta[8].Chemerinalso has been identified in vivo in 
human ovarian follicles and, more particularly, in 
granulosa and theca cells and follicular fluid. Chemerin 
inhibited IGF-1-induced progesterone and estradiol 
secretion as well as cell proliferation [9]. 
Oxidative stress has been identified to play a key role in 
the pathogenesis of subfertility in females. This 
imbalance between pro-oxidants and antioxidants can 
lead to a number of reproductive diseases such as 
endometriosis, PCOS, and unexplained infertility [10]. 
Human serum paraoxonase-1 (PON1) is a 
Ca2+dependent high-density lipoprotein (HDL) 
associated lactonase capable ofhydrolyzing a wide 
variety of lactones, thiolactones, arylesters, cyclic 
carbonates and organophosphate pesticides, nerve gases 
such as sarin and soman, glucuronide drugs and 
oestrogen esters [11].There is a paucity of data on the 
oxidative status of patients with PCOS. Reduced 
antioxidant status and increased oxidative stress in 
women with PCOS have previously beenreported[12, 
13]. To the best of our knowledge the PON1 protein 
concentration has not been studied as yet in Egyptian 
PCOS patients. By knowing that PON1 activity is 
decreased in PCO patients, it was felt interesting to 
investigate quantitatively the enzyme protein in Egyptian 
PCOS patients. 
The aim of the present study was to evaluate chemerin, 
ADMA and PON1 levels in obese and non-obese 
Egyptian women with PCOS and age-matchedhealthy 
controls and to correlate their relationship with each 
otherand with clinical, metabolic, and hormonal 
parameters. 
  
Experimental 
Subjects 
In this prospective study, 60 patients with PCOS and 
30age matched healthy controls were analyzed. The 
patients with PCOS were divided into two groups 
according to body mass index (BMI) as obese (BMI more 
than 30 kg/m2, n=30) and non-obese (BMI less than 30 
kg/m2, n=30). They were attending the outpatient 
infertility clinic of Kasr Al Ainy Maternity Hospital, 
Cairo University, Cairo, Egypt. Control subjects were 
recruited from women visiting the clinic with infertility 
due to male factor. 
The subjects included in our study with age range 
between 20 and 35 years,nuligravida, not takingany 
medications (oral contraceptives, glucocorticoids, 
antiandrogens, insulin sensitizers, ovulation induction 
agents, or antiobesity drugs) that could affectthe 
biochemical profile and metabolic variables. Subjects 
were excluded if not matching the age range (less than 20 
or more than 35 years) and in cases of known medical 
problems as thyroid dysfunction, virilizing tumors, DM, 
hepatic dysfunction, renal dysfunction, and hypertension. 
Smokers were also excluded.  
The diagnosis of PCOS was based on the revised criteria 
of the Rotterdam consensus conference by at least two of 
the following three features: (i) oligo- or anovulation; (ii) 
clinical and/ or biochemical signs of hyperandrogenism; 
and (iii) polycystic ovaries after excluding other etiologies 
including hyperprolactinemia, non-classical congenital 
adrenal hyperplasia, Cushing’s syndrome, and androgen-
secreting tumor [14]. Oligomenorrhea and amenorrhea 
were defined as <8 spontaneous menstrual cycles per year 
and the absence of a menstrual period for three 
consecutive months. Clinical hyperandrogenismand 
hirsutism was evaluated using the modified Ferriman–
Gallwey score (patients with score > 8 were considered as 
hirsute) [15]. 
Transvaginal ultrasonography examination was done to 
confirm diagnosis of PCOS, regularly menstruating 
women were scanned in the early follicular phase (cycle 
days 3–5), oligo-/amenorrhoeic women were scanned 
either at random or between days 3 and 5 after a 
progestin-induced withdrawal bleeding. The size of 
follicles <10 mm was expressed as the mean of the 
diameters measured on the two sections. The criteria for 
polycystic ovaries required visualization of 12 or more 
follicles in each ovary measuring 2–9 mm in a diameter, 
and/or increased ovarian volume (>10 cm3).[16]. 
Written informed consent was obtained from all subjects 
before entering the study and approved by the ethical 
comity. 
Clinical characteristics and biochemical assays 
All candidates were subjected to personal history (name, 
age, marital state, parity, address), menstrual history 
(duration, cycle, amount, regularity, last menstrual period) 
and medical history for acne and hirsutism. The BMI was 
calculated as weight (kg)/height squared (m2).Blood 
pressure was measured in the sitting position after a rest 
period of at least5 min.  
Initially, blood samples (10 mL) were taken between 8:00 
and 10:00 a.m. Blood samples were obtained from the 
antecubital vein, after an overnight fasting on the second 
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or third day after a spontaneous or progesterone 
withdrawal menstrual cycle. 
Blood samples were taken into plain vacutainer clotted 
tubes, where sera were obtained by centrifugation within 
30 min at 4000 rpm for 10 min. Sera was separated, first 
for the measurement of luteinizing hormone (LH), 
follicle stimulating hormone (FSH) and estradiol 
determined using standard ELISA technique using a kit 
from ALPCO (USA). Other aliquoted sera were kept 
frozen at -80°C [17] until used for Chemerin (using 
standard ELISA technique using a kit provided by 
RayBio® (Norcross, GA, USA), ADMA (using standard 
ELISA technique using a kit provided by Sigma 
(Munich, Germany)and PON1 (using standard ELISA 
technique using a kit provided by Boster Immunoleader 
(Pleasanton, USA), determination. Intra-assay and 
interassay coefficients of variation were 4.7% and 7.3%, 
respectively for chemerin at the same time as they were 
8.2% and 9.8%, respectively for ADMA. 
Statistical Analysis 
All analysis and graphics were performed using Graphpad 
prism (windows version 5; Graphpad software 2007). 
(GraphPad Software, San Diego, USA).  Data are 
presented as mean ±standard deviation orpercentage.One-
way analysis of variancewas performed to evaluate 
differences between the groups. The Tukey test was used 
as the post hoc test. All data wereanalyzed for normality 
of distribution. Spearman correlationcoefficient was used 
to test the strength of associationsbetween different 
variables.Statistical significance was considered at 
P≤0.05. 
 
 Results
 
Table (1) 
Clinical, biochemical and hormonal characteristics of the PCOS and control obese and non obesegroups. 
Characteristics Control 
 non obese 
Control  
Obese 
PCOS 
 non obese 
PCOS 
obese 
Number 18 12 30 30 
Ageyears 26.3 ± 3.9 28.2 ± 4.1 24.7 ± 4.0 25.1 ± 4.5 
BMIkg ⁄m2 23.8 ± 0.528 32.1 ± 0.562 25.8 ± 0.484 35.9 ± 0.763 
LH mIU/mL 4.17 ± 0.235  3.44 ± 0.130  7.032 ± 0.191a,b 6.892±0.217a,b 
FSH mIU/mL 7.49 ± 0.261  7.43 ± 0.312  5.96 ± 0.170a,b 5.52 ± 0.180a,b 
LH/FSH ratio 0.57 ± 0.15 0.48 ± 0.12 1.2 ±  0.32a,b 1.3 ±  0.36a,b 
Estradiol pg/mL 50.2 ± 1.70  49.5 ± 1.38  60.7 ± 1.65a,b 63.2 ± 1.59a,b 
Chemerin ng ⁄mL 76.3 ± 3.57 119 ± 5.38 114 ± 4.52a,b 171 ± 14.7a,b,c 
ADMAµmol/L 0.452 ± 0.027 0.422 ± 0.033 0.585 ± 0.018a,b 0.679 ± 0.027a,b,c 
PON1pg/mL 214 ± 6.29 201 ± 9.39a 178 ± 3.38a 166 ± 3.96a,b 
Note: Values are expressed as mean ± SD. 
BMI: body mass index, LH: luteinizing hormone, FSH: follicular stimulatinghormone. 
asignificantly different from healthy control non obese group, at P ≤ 0.05. 
bsignificantly different from healthy control obese group, at P ≤ 0.05. 
csignificantly different from PCOS non obese group, at P ≤ 0.05. 
 
 
Clinical characteristics and pituitary-gonadal 
hormone levels 
In the present study, patients are distributed among groups 
as shown in table (1) and their clinical characteristics and 
biochemical parameters measured are listed in table 
(1).Data presented in table (1) revealed that LH levels in 
PCOS obese and non-obese patients were higher than 
healthy control non-obese subjects by (165% and 169%, 
respectively) (P≤0.05) and higher than healthy control 
obese subjects by (200% and 204%, respectively) 
(P≤0.05) Whereas, FSH levels decreased significantly in 
the PCOS groups to 5.96 ± 0.170 mIU/mL and 5.52 ± 
0.180 mIU/mL for non-obese and obese 
womenrespectively (P≤0.05) from healthy control non 
obese level 7.49 ± 0.261 mIU/mL and healthy control 
obese level 7.43 ± 0.312 mIU/mL. 
Also LH/FSH ratio were higher in PCOS obese and non-
obese patients than healthy control non-obese subjects by 
(228% and 210%, respectively) (P<0.0001) and higher 
than healthy control obese subjects by (270% and 250%, 
respectively) (P<0.0001) 
However  estradiol levels in PCOS patients obese and 
non-obese were 63.2 ± 1.59 pg/mL and 60.7 ± 1.65 
pg/mL, respectively, being higher than the healthy control 
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non obese subjects level (50.2 ± 1.70 pg/mL) (P≤0.05) 
and healthy control obese subjects level (49.5 ± 1.38 
pg/mL) (P≤0.05). 
Chemerin, ADMA and PON1 levels 
Our study revealed that PCOS obese patients showed a 
significant increase in serum chemerin levels (171 ± 14.7 
ng/mL) when compared to PCOS non obese patients and 
healthy controls non obese and obese (114 ± 4.52, 76.3 ± 
3.57, 119 ± 5.38 ng/mL) respectively at P ≤0.05. On the 
contrary, serum chemerin  levels of healthy controls  
obese patients increased  by 156 % and 104 % when 
compared to the healthy control  non obese group  and 
PCOS non obese respectively at P ≤0.05. To add more 
insight into chemerin results, there was significant 
difference in serum chemerin levels between PCOS obese 
patients when compared to PCOS non obese patients by 
150 % at P ≤0.05. These results are illustrated in figure 
(1). As obvious in figure (2) serum ADMA level was 
increased significantly in PCOS obese group (0.679 ± 
0.027 µmol/L) as compared to the PCOS non obese 
group(0.585 ± 0.018 µmol/L) as well as the control non 
obese group (0.452 ± 0.027 µmol/L) and control obese 
group (0.422 ± 0.033 µmol/L) at P≤0.05. Paraoxonase 
as antioxidant marker was decreased stepwise 
significantly from the control non obese group level 214 ± 
6.29 pg/mL and control obese group level 201 ± 9.39 
pg/mL to PCOS non obese patients 178 ± 3.38 pg/mL 
then PCOS obese patients to 166 ± 3.96 pg/mL at P 
≤0.05. These results are demonstrated in figure (3). 
 
Figure (1): Chemerin  levels  
of the studied groups 
Figure (2): ADMA levels  
of the studied groups 
Figure (3): Paraoxonase levels  
of the studied groups 
a
 Significantly different from healthy control non obese group, at P ≤ 0.05. 
b
 Significantly different from healthy control obese group, at P ≤ 0.05. 
c
 Significantly different from PCOS non obese group, at P ≤ 0.05. 
 
Correlation of serum Chemerin, ADMA andPON1levels 
We correlated chemerin serum level with serum ADMA. 
In PCOS patients obese and non-obese, a significant 
positive correlation was observed between chemerin 
serum level and ADMA, whose r=0.388 at p=0.034 and 
r=0.393 at p=0.032, respectively, as illustrated in figures 
(4) and (5).Significant negative correlation was observed 
between PON1serum level and ADMA, whose r=-0.499 
at p=0.005 as demonstrated in figure (6).  
Moreover significant negative correlation was observed 
between PON1serum level and chemerin, whose r=0.402 
at p=0.028 as demonstrated in figure (7). 
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Figure (4): Correlation between serum chemerin and 
ADMA levels in obese women with PCOS 
Figure (5): Correlation betweenserum chemerin and 
ADMA levels in non-obese women with PCOS 
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Figure (6): Correlation betweenserum PON1 and 
ADMA levels in obese women with PCOS 
Figure (7): Correlation betweenserum chemerin and 
PON1 levels in obese women with PCOS 
 
Discussion 
Women with PCOS present a diverse combination of 
clinical complications including, psychological problems, 
reproductive alterations, and metabolic abnormalities 
including hyperinsulinemia, insulin resistance, 
dyslipidemia and obesity [18]. The relationships between 
PCOS and obesity, insulin resistance and endothelial 
dysfunction have complex features [19]. 
The present results revealed significant increase in serum 
LH and significant decrease in FSH in PCOS patients 
compared with control subjects. 
 These results agree withMohamadin et al., (2010), Azziz 
et al., (2009) and Lewandowski et al., (2011) who 
postulated that this phenomenon might be potentially 
useful as an additional tool in the diagnosis of PCOS[20, 
21 22]. In the present study it was found that LH is 
higher in patients with PCOS than in the control subjects, 
this was in accordance with a study done by Li and Lin, 
who found that LH was higher in obese women with 
PCOS when compared with non-obese PCOS patients 
and normal control subjects [23].Another study done by 
Samy et.al. who investigated hormonal profile in obese 
and non-obese PCOS patients and compared them to 
control normal subjects they found that increased levels 
of LH compared to healthy BMI matched controls [24]. 
There have been conflicts regarding the abnormalities of 
the hypothalamic-pituitary-ovarian (HPO) axis in women 
with PCOS. Anovulation is associated with disturbances 
in the feedback from the ovarian steroid hormones to the 
hypothalamus and pituitary, resulting in disturbances in 
the pulsatility of gonadotropin releasing hormone 
(GnRH). Gonadotropin-secretory changes, with a 
characteristic increase in LH relative to FSH release, 
have long been recognized in PCOS. It has also been 
suggested that the elevated concentrations of LH are due 
to an abnormal feedback by estrogen which may also 
induce thecal hyperplasia as LH stimulates theca cell 
proliferation [25-28]. 
A significant increase in serum estradiol level was 
noticed among our PCOS group and this finding may 
support the postulation that adipose tissue aromatase is 
involved in this relationship. The excess of adipose tissue 
in obese patients creates the paradox of having both 
excess androgens (which are responsible for hirsutism 
and virilization) and estrone (which inhibits FSH via 
negative feedback) [29]. 
Our study revealed that PCOS obese patients showed a 
significant increase in serum chemerinlevels when 
compared to PCOS non obese patients and healthy 
controls non obese and obese  subjects and  there was 
significant difference in serum chemerin levels between 
PCOS obese patients when compared to PCOS non obese 
patients by 150 % . 
Tan et al have demonstrated an increase of serum and 
subcutaneous and omental adipose tissue chemerin 
expression in women with PCOS [30]. Our finding was 
in harmony with results of Wang et al who have shown a 
higher level of chemein expression in the ovary of 
dihydrotestosterone induced PCOS rats [31]. Several 
experiments have demonstrated that chemerin may play a 
role in pathophysiology of PCOS in animal or human by 
direct action on ovary [32, 33]. It is well known that 
formation of polycystic ovaries is critically associated 
with abnormal steroidogenesis. It has been found that 
chemerin decreases estradiol secretion and suppressed 
FSH-induced progesterone and estradiol secretion in 
prenatal follicles and granulosa cells by inhibition of 
aromatase and p450scc expression [33]. It is also well 
recognized that development of polycystic ovaries is 
associated with new blood vessel formation although 
there is no data about the effect of chemerin on ovarian 
angiogenesis; however it is plausible that chemerin may 
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act as angiogenic factor [34].  By using an in vitro 
angiogenesis assay, it was shown that chemerin induced 
the formation of capillary like structures, a process which 
occur in obese patient and result in adipose tissue 
expansion [7]. These observations lead to the hypothesis 
that increasing the chemerin gene expression in ovary of 
PCOS rats may alter ovarian steroidogenesis or 
angiogenesis and may play a role in the development and 
progression of this reproductive disorder. Consistent with 
previous results, it could be hypothesized that chemerin 
has a role in PCOS development and manipulation of 
chemerin gene expression or its signaling may develop 
novel therapeutic approaches in the treatment of PCOS 
patients. 
In our study, PCOS patients were found to have 
significantly higher plasma ADMA levels. These high 
levels of ADMA may be explained by endothelial 
dysfunction caused by insulin resistance. Paradisi et al. 
reported endothelial dysfunction and insulin resistance in 
women with PCOS [35]. Orio et al. evaluated young 
PCOS patients with no metabolic and cardiovascular 
disease and reported disturbances in endothelial functions 
in the early period of the disease [36]. 
Our results are in agreement with Heutling et al., who 
demonstrated that plasma ADMA is increased in women 
with PCOS when compared to controls and decreased 
significantly after insulin sensitizer therapy (metformin) 
and suggested a close relationship between IR and 
plasma ADMA[37]. On the other hand, Demirel et al., 
(2007) demonstrated that serum ADMA was not different 
in adolescent subjects with PCOS and controls[38] and 
Turkcuoglu et al., (2011) who reported that plasma 
ADMA, nitric oxide levels and arginine/ADMA ratio 
were similar in PCOS and control groups[39]. In their 
study, plasma ADMA level did not correlate with the 
hormonal and metabolic parameters in patients with 
PCOS. Also, Pamuk et al., (2010) noticed that there were 
no significant difference in plasma ADMA level in obese 
patients with PCOS and healthy controls[40]. 
The possible mechanism of elevation of serum ADMA in 
PCOS is not well understood. It may be due to reduced 
renal excretion [41]and decreased activity of hydrolase 
enzyme which metabolizes ADMA [42]. As consequence 
of IR, PCOS patients have an abnormal lipid profile so 
IR may, contribute in directly to endothelial dysfunction 
and cardiovascular risk [20]. 
Moreover, the Correlation between serum chemerin and 
ADMA levels in obese and non-obese women with 
PCOS shows that chemerin may be used as an early 
marker of endothelial dysfunction better than ADMA. 
This suggestion is based on the correlation results which 
clearly demonstrate a wider ascending chemerin range 
that covers non-obese and obese PCOS patients than that 
of ADMA levels (figure 4 & 5). 
The results of the current study indicate that PON1 levels 
was significantly decreased in patients with PCOS when 
compared with healthy controls. In previous studies, 
reduced serum PON1 activity has been reported to be 
associated with insulin resistance [13].These results 
agree with Mohamadin et al., (2010)who found that 
PON1 activitywas significantly decreased in patients 
with PCOS whencompared with healthy controls[20]. 
Mohamadin et al, reported that serum PON1 activity, 
HDL-C and total antioxidant capacity were significantly 
lower in patients with PCOS than healthy controls [20]. 
Recently, PON1 became the focus of intense research 
after the identification of its antioxidant properties, 
particularly its capacity to protect LDL from oxidative 
damage [43]. 
Many studies that have addressed oxidative stress and 
PCOS to date have not given a definitive conclusion 
about their possible association [44]. Moreover, many 
different circulating markers used to estimate oxidative 
stress and the frequent finding of conflicting results 
across studies addressing the same markers may explain 
why the question of whether or not PCOS is associated 
with oxidative stress still remains open. 
The resultant oxidative stress causes extensive cellular 
injury, demonstrated by protein oxidation, lipid 
peroxidation, and DNA damage. This oxidative stress 
may directly stimulate hyperandrogenism. Additionally, 
serum total antioxidant status, is diminished in women 
with polycystic ovary syndrome, decreasing the body’s 
defense against an oxidative environment [45]. 
In the present study, there is a significant negative 
correlation between PON1 and chemerin in obese PCOS 
which indicate the association between obesity and 
decreased body antioxidant defense mechanisms.This 
concept is consistent with Aslan et al., (2011) and 
Adriana, (2014)[46, 47]. 
In conclusion, our study showed that obese and non-
obese women with PCOS have increased serum chemerin 
and ADMA with a strong positive correlation. In 
addition, decreased PON1 levels were observed in obese 
and non-obese PCOS with a strong negative correlation. 
These findings may indicate that women with PCOS are 
at high risk for oxidative stress, vascular 
endothelialdysfunction which is further aggravated by 
obesity. 
However further studies are recommended to elucidate 
the role of chemerin gene expression in PCOS patients 
and its possible drug intervention. 
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